🏅 FDA Orphan Designation
Cystaran
Cysteamine hydrochloride
Manufacturer: Leadiant Biosciences, Inc.
FDA-Approved Indications (2)
Adenovirus infection in immunocompromised patientsOrphan Designation
Treatment of corneal cystine crystal accumulation in patients with cystinosis
indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis
Population: all ages
Indications & Usage
1 INDICATIONS AND USAGE CYSTARAN ® is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. CYSTARAN is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. ( 1 )
💙 Support Programs
View all →Cystaran
Leadiant Biosciences, Inc.
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.